Scancell Partners with NHS Cancer Vaccine Launch Pad to Accelerate Melanoma Vaccine Trial
Why we think this is neutral
This RNS announcement is a general update on Scancell's partnership with the NHS Cancer Vaccine Launch Pad to fast-track access for NHS patients into the fourth cohort of the Company's Phase 2 clinical SCOPE study. While this is positive news for the company's cancer vaccine development, the announcement does not contain any specific financial or trading updates that would warrant a stronger sentiment score.
Key Points
- Partnership with NHS Cancer Vaccine Launch Pad to fast-track access for NHS patients into the fourth cohort of the Company's Phase 2 clinical SCOPE study
- The fourth cohort will evaluate intradermal administration of Scancell's iSCIB1+, a potent, targeted "off-the-shelf" Immunobody® second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments
- The CVLP is a world-leading NHS trial "matchmaking" service to help find new life-saving treatments, and Scancell is the first British company to join the CVLP
- iSCIB1+ is the first DNA vaccine to be part of this CVLP initiative
Summary
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, has announced a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company's Phase 2 clinical SCOPE study. This cohort will evaluate intradermal administration of Scancell's iSCIB1+, a potent, targeted "off-the-shelf" Immunobody® second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments.